Wed, Mar 4, 2015, 4:25 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Itron, Inc. Message Board

ehaninc 7 posts  |  Last Activity: Jan 9, 2015 12:30 PM Member since: Apr 29, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Apollo Fair Value $24.2

    by ehaninc Oct 24, 2014 12:38 PM
    ehaninc ehaninc Jan 9, 2015 12:30 PM Flag

    New Fair Value one year out is $24.23, barely budged since October
    FY2 consensus estimate = 1.97, a slight increase
    SP 500 p/e one year forward now down to 16.4 with earnings increasing since the fall.
    5 year relative p/e is up to .57, but lets keep it at 0.75 assuming optimism for APOL's future
    Fair Value = 1.97 * 16.4 * .75 = $24.23
    APOL would be a potential buy under $20

  • ehaninc ehaninc Dec 19, 2014 3:20 PM Flag

    Are you aware of anyone who has ben harmed by their trials? It may be a subjective opinion you are making.

  • http://www.fda.gov/downloads/Drugs/Guidances/UCM269919.pdf
    Copied from page 4:
    ICH E6 and ISO 14155:2011 specifically provide for flexibility in how trials are monitored. ICH
    E6 and ISO 14155:2011 advise sponsors to consider the objective, design, complexity, size, and
    endpoints of a trial in determining the extent and nature of monitoring for a given trial.13,14 The
    ISO standard further states that a sponsor’s assessment of these factors should be used to develop
    a monitoring plan, a recommendation consistent with FDA’s recommendation for monitoring
    plan development in this guidance. Although the ICH guidance and ISO standard specifically
    provide for the possibility of reduced, or even no, on-site monitoring, they also make clear that it
    would be appropriate to rely entirely on centralized monitoring only in exceptional
    circumstances.

  • Reply to

    The skinny on STEM

    by ehaninc Dec 16, 2014 2:03 PM
    ehaninc ehaninc Dec 19, 2014 12:25 PM Flag

    Wrong again. These are not my opinions, all of these comments came from STEM investor relations - this week. Either STEM is lying or you are a real blowhard. I'll believe the later until information proves otherwise.

  • Reply to

    The skinny on STEM

    by ehaninc Dec 16, 2014 2:03 PM
    ehaninc ehaninc Dec 17, 2014 11:47 AM Flag

    You are wrong on both accounts

  • Any company in phase I/II trials is speculative. STEM is no exception. Focus is on the spine and eyes and more info on that will not come out for several more months. So far both areas have showed progress over the last year. The end of the Alzheimer's study is not a surprise. No company has showed progress in that area and it was costing STEM cash above and beyond the funding they received. Cash flow is sufficient for another 9 months. Whistleblower suit seems like a long shot for a small company like STEM which does not have to hold up to the same standards of a large Pharma. The FDA has not stopped the research.
    Sell STEM if you think they will not successfully complete phase II trials, Buy STEM if you think there are possibilities of success.

    Sentiment: Hold

  • ehaninc by ehaninc Dec 12, 2014 9:31 PM Flag

    .... It's macular degeneration and spinal cords. Alzheimer's was a minor area for them.

ITRI
36.63-0.03(-0.08%)4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.